NeurogesX Completes Phase 2 Enrollment of NGX-1998 Topical Liquid Capsaicin Formulation Trial

NeurogesX, Inc. NGSX today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia. NGX-1998 is being developed to provide safety, efficacy and tolerability that is at least comparable to Qutenza 8% patch with a shorter treatment time. A total of 183 patients were enrolled in the Phase 2 study.